Skip to main content
SpringerLink
Log in

Kombinationen in der Behandlung forensischer Patienten

  • Chapter
  • First Online:
Polypharmazie in der Behandlung psychischer Erkrankungen

  • 2407 Accesses

Zusammenfassung

Ein erheblicher Teil forensisch-psychiatrischer Patienten erhält eine Medikation im Sinne einer Polypharmazie. Obschon in jüngster Zeit verstärkt auf die möglichen Vorteile einer solchen Behandlung hingewiesen wurde, muss die genaue Prüfung des Einzelfalles belegen, ob die damit verbundenen Nachteile, wie etwa schwierigere Steuerbarkeit der Medikation und Probleme hinsichtlich der Kontinuität der Behandlung, dies aufwiegen. Angesichts der mitunter notwendigen raschen Krisenintervention zur Vermeidung von Redelinquenz ist die verlässliche und nachvollziehbare Steuerbarkeit einer Monotherapie vorzuziehen, sofern sich durch die zusätzliche Gabe weiterer Präparate nicht eindeutige Vorteile ergeben.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 69.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 89.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Literatur

  • Agelink MW, Kavuk I, Ak I (2004) Clozapine with amisulpride for refractory schizophrenia. Am J Psychiatry 161: 924–925

    Article  PubMed  Google Scholar 

  • Barbui C, Nosè M, Mazzi MA, Thornicroft G, Schene A, Becker T, Bindman J, Leese M, Helm H, Koeter M, Weinmann S, Tansella M (2006). Persistence with polypharmacy and excessive dosing in patients with schizophrenia treated in four European countries. Int Clin Psychopharmacol 21(6): 355–62

    Article  PubMed  Google Scholar 

  • Birnbacher D, F.-J. BormannFJ, Dabrock P et al. (2013) Zwangsbehandlung bei psychischen Erkrankungen. Stellungnahme der Zentralen Kommission zur Wahrung ethischer Grundsätze in der Medizin und ihren Grenzgebieten (Zentrale Ethikkommission) bei der Bundesärztekammer

    Google Scholar 

  • Bondolfi G, Dufour H, Patris M, May JP, Billeter U, Eap CB, Baumann P (1998) Risperidne versus clozapine in treatment-resistent chronic schizophrenia: a randomized double-blind study. Am J Pychiatry 155: 499–504

    Article  CAS  Google Scholar 

  • Böker W, Häfner H (1973) Gewalttaten Geistesgestörter. Springer, Berlin, Heidelberg, New York

    Google Scholar 

  • Casey D (1996) “Seroquel” (quetiapine): preclinical and clinical findings of a new atypical antipsychotic. Exp Opin Invest Drugs 5: 939–957

    Article  CAS  Google Scholar 

  • Cheung HK (1981) Schizophrenics fully remitted on neuroleptics for 3 to 5 years: to stop or continue drugs? Br J Psychiatry 138: 490–494

    Article  CAS  PubMed  Google Scholar 

  • Citrome L, Levine J, Allingham B (2000) Changes in use of valproate and other mood stabilizers tor patients with schizophrenia from 1994 to 1998. Psychiatr Serv 51: 634–638

    Article  CAS  PubMed  Google Scholar 

  • Correll CU, Rummel-Kluge C, Corves C, Kane JM, Leucht S (2009) Antipsychotic Combinations vs Monotherapy in Schizophrenia: A Meta-analysis of Randomized Controlled Trials. Schizophr Bull 35(2): 443–57

    Article  PubMed  Google Scholar 

  • Cramer JA, Rosenheck R (1998) Compliance with medication regimes for mental and physical disorders. Psychiatric Services 49: 196–201

    Article  CAS  PubMed  Google Scholar 

  • Dickerson FB, Boronow JJ, Ringel NB, Parente F (1999) Social functioning and neurocognitive deficits in outpatients with schizophrenia: clinical and utilization correlates. Acta Psychiatr Scand 98: 124–127

    Article  Google Scholar 

  • Dencker SJ, Lepp M, Malm U (1980) Do schizophrenics well adapted in the community need neuroleptics? A depot neuroleptic withdrawl study. Acta Psychiatr Scand 279: 64–76

    CAS  Google Scholar 

  • Fenton WS, Blyler CR, Heinssen RK (1998) Prealence of spontaneous dyskinesia in schizophrenia. J Clin Psychiatry 61 (suppl 4): 4–10

    Google Scholar 

  • Freese R (2003) Ambulante Versorgung von psychisch kranken Straftätern im Maßregel- und Justizvollzug – Analysen, Entwicklungen, Impulse. Recht & Psychiatrie 21: 52–57

    Google Scholar 

  • Fromberger P, Jordan K, Steinkrauss H, von Herder J, Witzel J, Stolpmann G, Müller JL (2012) Diagnostic accuracy of eye movements in assessing pedophilia. J Sex Med, 9(7): 1868–82

    Article  PubMed  Google Scholar 

  • Gallhofer B, Bauer U, Lis S, Krieger S, Gruppe H (1996) Cognitive dysfunction in schizophrenia: comparison in treatment with atypical antipsychotic agents and conventional neuroleptic drugs. Eur Neuropsychopharmacol 6: 13–20

    Article  Google Scholar 

  • Gefvert O, Bergstrom M, Laangstrom B, Lundberg T, Lindstrom L, Yates RA (1998) Time course of central nervous Dopamine-D2 and 5-HAT receptor blockade and plasma drug concentrations after discontinuation of quetiapine in patients with schizophrenia. Psychopharmacology 135: 119–126

    Article  CAS  PubMed  Google Scholar 

  • Glick ID, Pham D, Davis JM (2006) Concomitant medications may not improve outcome of antipsychotic monotherapy for stabilized patients with nonacute schizophrenia. J Clin Psychiatry 67(8): 1261–5

    Article  CAS  PubMed  Google Scholar 

  • Hässler F, Buchmann J, Bohne S (2002) Möglichkeiten und Grenzen der Behandlung aggressiven Verhaltens bei Menschen mit geistiger Behinderung mit Risperidon. Nervenarzt 73(3): 278–82

    Article  PubMed  Google Scholar 

  • Hanson RK (2001) Sex offender risk assessment. In: Hollin CR (Hrsg.) Handbook of offender assessment and treatment. Chicester, New York, Weinheim

    Google Scholar 

  • Henderson DC, Goff DC (1996) Risperidone as an adjunct to clozapine therapy in chronic schizophrenics. J Clin Psychiatry 57: 395–397

    CAS  PubMed  Google Scholar 

  • Hirose S (2001) Effective treatment of aggression and impulsivity in antisocial personality disorder with risperidone. Psychiatry Clin Neurosci 55(2): 161–2

    Article  CAS  PubMed  Google Scholar 

  • Hogarty GE, Ulrich R, Mussare F, Aristigueta N (1976) Drug discontinuation among long-term, sucessfully maintained schizophrenic outpatients. Dis Nerv Syst 37: 494–500

    CAS  PubMed  Google Scholar 

  • Hogarty GE, Schooler N, Ulrich R, Mussare F, Ferro P, Herron E (1979) Fluphenazine and social therapy in the aftercare of schizophrenic patients. Relaps analysis of a two-year controlled study. Arch Gen Psychiatry 36: 1283–1294

    Article  CAS  PubMed  Google Scholar 

  • Hsu CY, Lin YH, Shen YC (2013) Tardive dyskinesia induced by a switch from haloperidol depot to paliperidone palmitate. Journal of Neuropsychiatry and Clinical Neuroscience, 1; 25(4): E46–7

    Google Scholar 

  • Huttunen M0, Tuhkanen H, Haavisto E, Nyholm R, Pitkanen M, Raitasuo V, Romanov M (1996) Low- and standard-dose depot haloperidol combined with targeted oral neuroleptics. Psychiatr Serv 47: 83–85

    Article  Google Scholar 

  • Incision B, Barbui C, Marmai L, Donà S, Grassi L (2007) Determinants of antipsychotic polypharmacy in psychiatric inpatients: a prospective study. Int Clin Psychopharmacol 22(2): 124

    Article  Google Scholar 

  • Ito C, Kubota Y, Sato M (1999) A prospective survey on drug choice for prescriptions for admitted patients with schizophrenia. Psychiatry Clin Neurosci 53 Suppl S35–S40

    Google Scholar 

  • Janssen B, Weinmann S, Berger M, Gaebel W (2004) Validation of polypharmacy process measures in inpatient schizophrenia care. Schizophr Bull. 30(4): 1023–33

    Article  PubMed  Google Scholar 

  • Janowsky DS, Barnhill LJ, Shetty M, Davis JM (2005) Minimally effective doses of conventional antipsychotic medications used to treat aggression, self-injurious and destructive behaviors in mentally retarded adults. J Clin Psychopharmacol. 25(1): 19–25

    Article  CAS  PubMed  Google Scholar 

  • Johnson DA (1976) The expectation of outcome from maintenance therapy in chronic schizophrenic patients. Br J Psychiatry 128: 246–250

    Article  CAS  PubMed  Google Scholar 

  • Jones AM, Rak IW, Raniwalla J, Phung D, Melvin K (2000) Weight changes in patients treated with „Seroquel“ (Quetiapine). Schizophr Res 41: B83

    Google Scholar 

  • Josiassen, RC, Joseph A, Kohegyi E, Stokes S, Dadvand M, Paing WW, Shaughnessy RA (2005) Clozapine augmented with risperidone in the treatment of schizophrenia: a randomized, double-blind, placebo-controlled trial. Am J Psychiatry 162: 130–136

    Article  PubMed  Google Scholar 

  • Kane JM (1995) Tardive dyskinesia: Epidemiological and clinical presentation. In: Bloom F, Kupfer D (Eds.) Psychopharmacology: The fourth generation of progress. New York, NY: Raven Press: 1485–1496

    Google Scholar 

  • Kane JM (1996) Schizophrenia. N Engl J Med 334: 34–41

    Article  CAS  PubMed  Google Scholar 

  • Kapur S, Zipursky RB, Remington G (1999) Clinical and theoretical implications of 5-HT2 and D2 receptor occupancy of clozapine, risperidone, and olanzapine in schizophrenia. Am J Psychiatry 156: 286–293

    CAS  PubMed  Google Scholar 

  • Kapur S, Zipursky RB, Jones C, Shammi CS, Remington G, Seeman P (2000) A positron emission tomography study of quetiapine in schizophrenia: a preliminary finding of an antipsychotic effect with only transiently high dopamine D2 receptor occupancy. Arch Gen Psychiatry 57: 553–559

    Article  CAS  PubMed  Google Scholar 

  • Katona L, Czobor P, Bitter I (2013) Real-world effectiveness of antipsychotic monotherapy vs. polypharmacy in schizophrenia: To switch or to combine? A nationwide study in Hungary. Schizophrenia Research Nov 22. [Epub ahead of print]

    Google Scholar 

  • Kaye NS (2003) Ziprasidone augmentation of clozapine in 11 patients. J Clin Psychiatry 64: 215–216

    Article  PubMed  Google Scholar 

  • Kennedy NB, Procyshyn RM (2000) Rational antipsychotic polypharmacy. Can J Clin Pharmacol 7: 155–159

    CAS  PubMed  Google Scholar 

  • Knable MB, Heinz A, Raedler T, Weinberger DR (1997) Extrapyramidal side effects with risperidone and haloperidol at comparable D2 receptor occupancy levels. Psychiatry Res 75: 91–101

    Article  CAS  PubMed  Google Scholar 

  • Konrad N (2005) Managing the mentally ill in the prisons of Berlin. International Journal of Prisoner Health, 1: 39–47

    Article  Google Scholar 

  • Konrad N (2007) Psychiatrische Konsiliartätigkeit im deutschen Justizvollzug. Psychosomatik und Konsiliarpsychiatrie 1: 216–219

    Google Scholar 

  • Kreyenbuhl JA, Valenstein M, McCarthy JF, Ganoczy D, Blow FC (2007) Long-term antipsychotic polypharmacy in the VA health system: patient characteristics and treatment patterns. Psychiatr Serv. 58(4): 489–95

    Article  PubMed  PubMed Central  Google Scholar 

  • Linden, M, Scheel, T, Xaver, EF (2004) Dosage finding and outcome in the treatment of schizophrenic inpatients with amisulpride. Results of a drug utilization observation study. Hum Psychopharmacol 19: 111–119

    Article  CAS  PubMed  Google Scholar 

  • Marinis TD, Saleem PT, Glue P, Arnoldussen WJ, Teijeiro R, Lex A, Latif MA, Medori R (2007) Switching to long-acting injectable risperidone is beneficial with regard to clinical outcomes, regardless of previous conventional medication in patients with schizophrenia. Pharmacopsychiatry 40(6): 257–63

    Article  PubMed  Google Scholar 

  • Markovitz PJ (2004) Trends in the pharmacotherapy of personality disorders. J Personal Disord 18(1): 90–101

    Article  Google Scholar 

  • McCue, RE, Waheed, R, Urcuyo, L (2003) Polypharmacy in patients with schizophrenia. J Clin Psychiatry 64: 984–-989

    Google Scholar 

  • Megna JL, Kunwar AR, Mahlotra K, Sauro MD, Devitt PJ, Rashid A (2007). A study of polypharmacy with second generation antipsychotics in patients with severe and persistent mental illness. J Psychiatr Pract. J Psychiatr Pract 13(2):129–37

    Article  PubMed  Google Scholar 

  • Messer T, Heger S, Schmauß M (2002) Risperidon Microspheres. Die Renaissance der neuroleptischen Depottherapie. Psychopharmakotherapie 4: 133–138

    Google Scholar 

  • Möller HJ, Müller H, Borison RL, Schooler NR, Chouinard G (1995) A path-analytical approach to differentiate between direct and indirect drug effects on negative symtoms in schizophrenia patients. A re-evaluation of the Nort American risperidone study. Eur Arch Psychiatry Clin Neurosci 245: 45–49

    Article  PubMed  Google Scholar 

  • Möller HJ, Benkert O, Gastpar M, Laux G, Rüther E (2002) Behandlungsleitlinie Psychopharmakotherapie. Steinkopff, Darmstadt

    Google Scholar 

  • Morgenstern H, Glazer WM (1993) Identifying risk factors for tardive dyskinesia among longterm outpatients maintained with neuroleptic medications. Arc Gen Psychiatry 50: 723–33

    Article  CAS  Google Scholar 

  • Morera AL, Barreiro P, Cano-Munoz JL (1999) Risperidone and clozapine combination tor the treatment of refractory schizophrenia. Acta Psychiatr Scand 99: 305–306

    Article  CAS  PubMed  Google Scholar 

  • Nedopil N (2000) Forensische Psychiatrie. Klinik, Begutachtung und Behandlung zwischen Psychiatrie und Recht. Thieme, Stuttgart, New York

    Google Scholar 

  • Northoff G, Witzel JG, Bogerts B (2006) Was ist „Neuroethik“ – eine Disziplin der Zukunft? Nervenarzt 77: 5–11

    Article  CAS  PubMed  Google Scholar 

  • Novakovic V, Adel T, Peselow E, Lindenmayer JP (2013) Long-acting injectable antipsychotics and the development of postinjection delirium/sedation syndrome (PDSS). Clinical Neuropharmacol.ogy 36(2): 59–62

    Google Scholar 

  • Nussbaum AM, Stroup TS (2012) Paliperidone palmitate for schizophrenia. Schizophrenia Bulletin 38(6): 1124–7

    Article  PubMed  PubMed Central  Google Scholar 

  • Park EJ, Amatya S, Kim MS, Park JH, Seol E, Lee H, Shin YH, Na DH (2013) Long-acting injectable formulations of antipsychotic drugs for the treatment of schizophrenia. Archives of Pharmacal Research 36(6): 651–9

    Article  CAS  PubMed  Google Scholar 

  • Patel JK, Salzman C, Green AI, Tsuang MT (1997) Chronic schizophrenia: response to clozapine, risperidone, and paroxetine. Am J Psychiatry 154: 543–546

    Article  CAS  PubMed  Google Scholar 

  • Peuskens J (1995) Risperidone in the treatment of patients wih chronic schizophrenia: A multi-national, multicentre, double-blind, parallel-group study versus haloperidol. Br J Psychiatry 166: 712–726

    Article  CAS  PubMed  Google Scholar 

  • Pelissolo A, Lepine JP (1999) Pharmacotherapy in personality disorders: methodological issues and results. Encephale 25(5): 496–507

    CAS  PubMed  Google Scholar 

  • Preskorn SH, Lacey RL (2007) Polypharmacy: when is it rational? J Psychiatr Pract 13(2): 97–105

    Article  PubMed  Google Scholar 

  • Procyshyn RM, Kennedy NB, Tse G, Thompson B (2001) Antipsychotic polypharmacy: a survey of discharge prescriptions tram a tertiary care psychiatric institution. Can J Psychiatry 46: 334–339

    Article  CAS  PubMed  Google Scholar 

  • Procyshyn RM, Thompson B (2004) Patterns of antipsychotic utilization in a tertiary care psychiatric institution. Pharmacopsychiatry 37: 12–17

    CAS  PubMed  Google Scholar 

  • Puri BK, Barnes TRE, Chapman MJ, Hutton SB, Joyce EM (1999) Spontaneous dyskinesia in first episode schizophrenia. J Neurol Neurosurg Psychiatry 66: 76–78

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Raskin S, Katz G, Zislin Z, Knobler HY, Durst R (2000) Clozapine and risperidone: combination/augmentation treatment of refractory schizophrenia: a preliminary observation. Acta Psychiatr Scand 101: 334–-336

    Google Scholar 

  • Rifkin A, Quitkin F, Rabiner C, Klein D (1977) Fluphenazine decanoate, fluphenazine hydrochloride given orally, and placebo in remitted schizophrenics: Relapse rates after one year. Arch Gen Psychiatry 34: 43–47

    Article  CAS  PubMed  Google Scholar 

  • Rittmannsberger H, Meise U, Schauflinger K, Horvath E, Donat H, Hinterhuber H (1999) Polypharmacy in psychiatric treatment. Patterns of psychotropic drug use in Austrian psychiatric clinics. Eur Psychiatry 14: 33–40

    Article  CAS  PubMed  Google Scholar 

  • Robertson J, Emerson E, Gregory N, Hatton C, Kessissoglou S, Hallam A (2000) Receipt of psychotropic medication by people with intellectual disability in residential settings. J Intellect Disabil Res 44 (6): 666–76

    Article  PubMed  Google Scholar 

  • Ros S, Díez B, Casanova N (2008) Anticonvulsants in the treatment of impulsivity. Actas Esp Psiquiatr. 2008 May-Jun; 36(3): 46–62

    Google Scholar 

  • Rossi A, Mancini F, Stratta P, Mattei P, Gismondi R, Pozzi F, Casacchia M (1997) Risperidone, negative symptoms and cognitive deficit in schizophrenia: an open study. Acta Psychiatr Scand 95: 40–43

    Article  CAS  PubMed  Google Scholar 

  • Schiltz K, Witzel JG, Northoff G, Zierhut K, Gubka U, Fellmann H, Kaufmann J, Tempelmann C, Wiebking C, Heinze H, Bogerts B (2007a) Brain Pathology in Pedophilic Offenders: Evidence of Volume Reduction in the Right Amygdala and Related Diencephalic Structures. Arch Psychiatry 64(6): 737–746

    Article  Google Scholar 

  • Schiltz K, Witzel JG, Bausch-Hölterhoff J, Bogerts B (2007b) Die Rolle neuropsychiatrischer Erkrankungen bei Gewaltdelinquenz. Forensische Psychiatrie und Psychotherapie 2: 65–82

    Google Scholar 

  • Schiltz K, Witzel JG, Bogerts B (2011) Neurobiological and clinical aspects of violent offenders. Minerva Psichiatrica 52(4): 187–203

    Google Scholar 

  • Schiltz K, Witzel JG, Bausch-Hölterhoff J, Bogerts (2013) High Prevalence of Brain Pathology in Violent Prisoners: A Qualitative CT- and MRI Scan Study. European Arch Psych Clin Neurosc, 263(7): 607–16

    Google Scholar 

  • Schooler N, Levine J, Severe J, Brauzer B, DiMascio A, Klerman G, Tuason V (1980) Prevention of relapse in schizophrenia. An evaluation of fluphenazine decanoate. Arch Gen Psychiatry 37: 16–24

    Article  CAS  PubMed  Google Scholar 

  • Seifert D, Möller-Mussavi S (2005) Aktuelle Rückfalldaten der Essener prospektiven Prognosestudie. Fortschr Neurol. Psychiat 73: 16–22

    CAS  Google Scholar 

  • Soyka M, Graz C, Bottlender, Dirschel P, Schoech H (2007) Clinical correlates of later violence and criminal offences in schizophrenia. Schizophrenia Research, 94: 89–98

    Google Scholar 

  • Supady A, Voelkel A, Witzel J, Gubka U, Northoff G (2011) How is informed consent related to emotions and empathy? An explanatory neuroethical investigation. Journal of Medical Ethics, 37(5): 311–7

    Article  PubMed  Google Scholar 

  • Suzuki T, Uchida H, Watanabe K, Vagi G, Kashima H (2004) A clinical case series of switching tram antipsychotic polypharmacy to monotherapy with a second-generation agent on patients with chronic schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 28: 361–369

    Article  CAS  PubMed  Google Scholar 

  • Suzuki T, Uchida H, Watanabe K, Nakajima S, Nomura K, Takeuchi H, Tanabe A, Yagi G, Kashima H (2008). Effectiveness of antipsychotic polypharmacy for patients with treatment refractory schizophrenia: an open-label trial of olanzapine plus risperidone for those who failed to respond to a sequential treatment with olanzapine, quetiapine and risperidone. Hum Psychopharmacol, Aug; 23(6): 455–63

    Article  CAS  PubMed  Google Scholar 

  • Taylor P, Gunn J (1984) Violence and Psychosis – risk of violence among psychotic men. British Medical Journal 288: 1945–1949

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Taylor CG, Flynn SW, Altman S, Ehmann T, MacEwan GW, Honer WG (2001) An open trial of risperidone augmentation of partial response to clozapine. Schizophr Res 48: 155–158

    Article  CAS  PubMed  Google Scholar 

  • The Scottish First Episode Schizophrenia Study (1987) II. Treatment: pimozide versus Flupentixol. The Scottish Schizophrenia Research Group. Br. J Psychiatry 150: 334–8

    Article  Google Scholar 

  • Tranulis C, Skalli L, Lalonde P, Nicole L, Stip E (2008) Benefits and risks of antipsychotic polypharmacy: an evidence-based review of the literature. Drug Saf. 31(1): 7–20

    Article  CAS  PubMed  Google Scholar 

  • Ustohal L, Prikryl R, Hublova V, Mayerova M, Kucerova HP, Ceskova E, Kasparek T (2013) Severe acute dystonia/akathisia after paliperidone palmitate application – a case study. International Journal of Neuropsychopharmacology, 24: 1–2

    Google Scholar 

  • Walker C, Thomas J, Allen TS (2003) Treating impulsivity, irritability, and aggression of antisocial personality disorder with quetiapine. Int J Offender Ther Comp Criminol. 47(5): 556–67

    Article  PubMed  Google Scholar 

  • Walter M, Witzel JG, Wiebking C, Gubka U, Rotte M, Schiltz K, Bermpohl F, Bogerts B, Heinze HJ, Northoff G (2007) Pedophilia is Linked to reduced Activation in Hypothalamus and Lateral Prefrontal Cortex During Visual Erotic Stimulation. Biological Psychiatry 62(6): 698–701

    Article  PubMed  Google Scholar 

  • Walter M, Ponseti J, Witzel J, Bogerts B (2010) Hirnbiologische Marker in der Diagnostik und Behandlung der Pädophilie und ihr Stellenwert für gesellschaftliche Maßnahmen gegen sexuellen Missbrauch von Kindern. Forensische Psychiatrie und Psychotherapie 1: 115–136

    Google Scholar 

  • Wang PS, West JC, Tanielian T, Pincus HA (2000) Recent patterns and predictors of antipsychotic medication regimens used to treat schizophrenia and other psychotic disorders. Schizophr Bull 26: 451–457

    Article  CAS  PubMed  Google Scholar 

  • Wilson WH (1995) Do anticonvulsants hinder clozapine treatment? Biol Psychiatry 37: 132–133

    Article  CAS  PubMed  Google Scholar 

  • Wirshing DA, Marshall BD, Green Mf, Mintz J, Marder SR, Wirshing WC (1999) Risperidone in treatment-refractory schizophrenia. Am J Psychiatry 156: 1374–1379

    CAS  PubMed  Google Scholar 

  • Wistedt B (1981) A depot neuroleptc withdrawl study: a controlled study of the clinical effects of the withdrawl of depot fluphenazine decanoate and depot flupentixol decanoate in chronic schizophrenic patients. Acta Psychiatr Scand 64: 65–84

    Article  CAS  PubMed  Google Scholar 

  • Witzel JG, Gubka U (2003) Modellprojekt einer stationären Akutbehandlung von psychisch kranken Häftlingen in einer speziell eingerichteten psychiatrischen Behandlungsabteilung in der JVA Werl. Krankenhauspsychiatrie 14: 19–23

    Article  Google Scholar 

  • Witzel JG, Bausch-Hölterhoff J, Skirl M (2004) Zur Situation des psychisch Kranken in Haft in Nordrhein-Westfalen. Forensische Psychiatrie und Psychotherapie 3: 53–67

    Google Scholar 

  • Witzel JG, Northoff G, Diekmann K, Bogerts B (2005) Sexualstraftäter im Maßregelvollzug des Landes Landes Sachsen-Anhalt: statistische Bestandsaufnahme aus den Jahren 1992–2004 und Schlussfolgerungen. Forensische Psychiatrie und Psychotherapie 2: 33–50

    Google Scholar 

  • Witzel JG (2006) Einsatz von Neuroleptika in der Forensischen Psychiatrie – Ergebnisse einer Untersuchung im Landeskrankenhaus für Forensische Psychiatrie Uchtspringe. Forensische Psychiatrie und Psychotherapie 2: 123–135

    Google Scholar 

  • Witzel JG, Huppertz M (2007) Lochow – ein neuer Weg aus einer alten Misere? Eine neue Konzeption für den Maßregelvollzug in Sachsen-Anhalt. Forensische Psychiatrie und Psychotherapie 2: 97–116

    Google Scholar 

  • Witzel J, Walter M, Bogerts B, Northoff G (2008a) Neurophilosophical perspectives of Neuroimaging in Forensic Psychiatry – giving way to a paradigm shift? Behavioral Sciences & the Law 26(1): 113–130

    Article  Google Scholar 

  • Witzel JG (2008b) Eine neues Behandlungsmodell für den Maßregelvollzug in Sachsen-Anhalt. Gemeindenahe Psychiatrie 2: 61–68

    Google Scholar 

  • Witzel JG, Gubka U, Weisser H, Bogerts B (2008c) Antipsychotic Polypharmacy in the Emergency Treatment of highly aggressive schizophrenic Prisoners – a retrospective Study. International Journal of Prisoner Health 4(2): 96–103

    Article  PubMed  Google Scholar 

  • Witzel JG, Gubka U, Bogerts B (2008d) Zunahme schizophrener Störungen bei vorläufig Untergebrachten (§ 126a StPO) in der Forensischen Psychiatrie – Trendwende oder Zufälligkeit? Der Nervenarzt (Supplement 4), 79: 482

    Google Scholar 

  • Witzel JG, Krüger S, Zander N, Bogerts B (2008e) Kosten medikamentöser Behandlung in der Forensischen Psychiatrie. Der Nervenarzt (Suppl. 4); 79:482–3

    Google Scholar 

  • Witzel J, Held E, Bogerts B (2009a) Electroconvulsive therapy in Forensic Psychiatry – Ethical problems in daily practice. The Journal of ECT, 25(2): 129–132

    Article  PubMed  Google Scholar 

  • Witzel JG (2009b) Medizin und Arzt im Maßregelvollzug; Psychiatrischer Konsiliardienst. In: Keppler/Stöver, Gefängnismedizin, 1. Auflage Thieme : 223–227

    Google Scholar 

  • Witzel JG (2013) Multiple Medication Use of Neuropsychiatry in Forensic Psychiatry. In: Polypharmacy in Psychiatry Practice, Volume 1. Multiple Medication Use Strategies, Michael Ritsner, Ed. Springer

    Google Scholar 

  • Xiang YT, Weng YZ, Leung CM, Tang WK, Ungvari GS (2007) Clinical and social determinants of antipsychotic polypharmacy for Chinese patients with schizophrenia. Pharmacopsychiatry 40(2): 47–52

    Article  CAS  PubMed  Google Scholar 

  • Yamauchi K, Baba K, Ikegami N, Miyaoka H, Kamijima K (1998) A survey of drug utilization in psychiatric hospitals in Japan: the basic analysis of the current status of prescription patterns. Seishin Shinkeigaku Zasshi 100: 51–68

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Landeskrankenhaus für Forensische Psychiatrie Uchtspringe, Schnöggersburger Weg 1, 39576, Hansestadt Stendal, Deutschland

    Dr. med. Joachim G. Witzel

Authors
  1. Dr. med. Joachim G. Witzel
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Joachim G. Witzel .

Editor information

Editors and Affiliations

  1. Danuvius Klinik Pfaffenhofen, Pfaffenhofen, Germany

    Thomas Messer

  2. und Psychosomatik, Bezirkskrankenhaus Augsburg Klinik für Psychiatrie, Psychotherapie,, Augsburg, Germany

    Max Schmauß

Rights and permissions

Reprints and permissions

Copyright information

© 2016 Springer-Verlag Wien

About this chapter

Cite this chapter

Witzel, J. (2016). Kombinationen in der Behandlung forensischer Patienten. In: Messer, T., Schmauß, M. (eds) Polypharmazie in der Behandlung psychischer Erkrankungen. Springer, Vienna. https://doi.org/10.1007/978-3-7091-1849-8_9

Download citation

  • DOI: https://doi.org/10.1007/978-3-7091-1849-8_9

  • Published:

  • Publisher Name: Springer, Vienna

  • Print ISBN: 978-3-7091-1848-1

  • Online ISBN: 978-3-7091-1849-8

  • eBook Packages: Medicine (German Language)

Publish with us

Policies and ethics

Search

Navigation